WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical, Inc. (the 'Company') (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a three-year product purchase agreement with Sanderling Renal Services, Inc.

威斯康星州威斯康星州-罗克韦尔医疗公司（“公司”）（纳斯达克股票代码：RMTI）是一家医疗保健公司，向全球透析提供者开发，制造，商业化和分销血液透析产品组合，今天宣布该公司与Sanderling Renal Services，Inc。签订了为期三年的产品购买协议。

('Sanderling'), a full-service provider of in-center, home dialysis and renal telemedicine services focusing on patients in rural and underserved communities across the United States..

（'Sanderling'），一家提供中心，家庭透析和肾脏远程医疗服务的全方位服务提供商，专注于美国农村和服务不足的社区患者。。

Under the terms of this agreement, which includes supply and purchasing commitments and has the potential to generate millions of dollars in net sales for Rockwell Medical over the course of the contract, Rockwell Medical will be the preferred supplier of liquid and dry acid and bicarbonate hemodialysis concentrates to Sanderling's facilities located throughout California, Colorado, Nevada, Oklahoma, Tennessee, Illinois, and Utah.

根据本协议的条款，包括供应和采购承诺，并有可能在合同期间为Rockwell Medical产生数百万美元的净销售额，Rockwell Medical将成为液体和干酸以及碳酸氢盐血液透析的首选供应商将集中到Sanderling位于加利福尼亚州，科罗拉多州，内华达州，俄克拉荷马州，田纳西州，伊利诺伊州和犹他州。

In addition to supplying hemodialysis concentrates and concentrates accessories, Rockwell Medical will also provide Sanderling with its DAMX45 Dry Acid Concentrate Mixer units to support Sanderling's preference to conveniently mix acid concentrate on-site..

除了提供血液透析浓缩液和浓缩液附件外，Rockwell Medical还将为Sanderling提供DAMX45干酸浓缩液混合器单元，以支持Sanderling优先在现场方便地混合酸浓缩液。。

'Sanderling provides in-center and home-based dialysis out of clinics that are located in USDA-defined rural areas with limited access to healthcare resources,' said Dr. Jerome Tannenbaum, Founding Chairman and CEO of Sanderling. 'We continue to look to expand our services in existing markets while moving into new communities to broaden our access to dialysis patients through our telemedicine and eDialysis offerings.

Sanderling的创始主席兼首席执行官Jerome Tannenbaum博士说：“Sanderling在美国农业部定义的农村地区的诊所提供中心和家庭透析，这些诊所的医疗资源有限。”我们继续寻求扩大现有市场的服务，同时进入新社区，通过我们的远程医疗和透析产品扩大我们接触透析患者的机会。

Hemodialysis concentrates are critical to vulnerable patients with ESKD. Partnering with Rockwell Medical ensures that we are able to provide our clinics and their patients with the highest quality products supported by the best customer service in the industry.'.

血液透析浓缩物对易患ESKD的患者至关重要。与Rockwell Medical合作确保我们能够为诊所及其患者提供由行业最佳客户服务支持的最高质量产品。

'Sanderling is renowned for bringing high-quality medical services to communities with limited access to healthcare sources,' said Tim Chole, Senior Vice President, Sales and Marketing at Rockwell Medical. 'We are proud to partner with Sanderling and support its innovative approach to the care of end-stage kidney disease patients in rural and other underserved populations.'.

“Sanderling以向医疗保健来源有限的社区提供高质量医疗服务而闻名，”Rockwell medical销售和营销高级副总裁Tim Chole说我们很自豪与Sanderling合作，并支持其在农村和其他服务不足人群中照顾终末期肾病患者的创新方法。

About Rockwell Medical

关于Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry.

Rockwell Medical，Inc。（纳斯达克股票代码：RMTI）是一家医疗保健公司，为全球透析供应商开发，制造，商业化和分销血液透析产品组合。罗克韦尔医疗的使命是为透析诊所及其服务的患者提供由行业最佳客户服务支持的最高质量产品。

Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home.

罗克韦尔专注于创新的长期增长战略，以增强其产品，流程和人员，使公司能够为医疗保健系统提供卓越的价值，并对血液透析患者的生活产生积极影响。血液透析是终末期肾病治疗的最常见形式，通常在独立的门诊透析中心，医院门诊中心，熟练的护理设施或患者家中进行。

Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Rockwell Medical is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States and intends to become the leading global supplier of hemodialysis concentrates.

Rockwell Medical的产品对易患终末期肾病的患者至关重要，该公司不懈地提供无与伦比的可靠性和客户服务。Rockwell Medical是美国透析患者用酸和碳酸氢盐浓缩物的第二大供应商，并打算成为全球血液透析浓缩物的领先供应商。

Certified as a Great Place to Work® in 2023, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis SolutionsTM. For more information, visit www.RockwellMed.com..

在2023年被认证为一个很好的工作场所®，Rockwell Medical将推出维持生命的透析解决方案TM。欲了解更多信息，请访问www.RockwellMed.com。。

Forward-Looking Statements

前瞻性声明

Certain statements in this press release may constitute 'forward-looking statements' within the meaning of the federal securities laws. Words such as, 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'could,' 'can,' 'would,' 'develop,' 'plan,' 'potential,' 'predict,' 'forecast,' 'project,' 'intend,' 'look forward to,' 'remain confident,' “are determined,” “are on track,” “are resolute in our vision,” 'work to,' 'drive towards,' “focused on,” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements.

本新闻稿中的某些声明可能构成联邦证券法含义内的“前瞻性声明”。诸如“可能”，“可能”，“将会”，“应该”，“相信”，“期望”，“预期”，“估计”，“继续”，“可以”，“可以”，“将会”，“发展”，“计划”，“潜力”，“预测”，“预测”，“项目”，“打算”，“期待”，“保持信心”，“确定”，“正在进行中”，“在我们的愿景中坚决，“努力”，“推动，“专注于”或这些术语的否定性，以及类似的表达方式，或关于意图，信念或当前期望的陈述，都是前瞻性陈述。

There can be no assurance that Rockwell Medical will become the leading global supplier of hemodialysis concentrates or will generate the expected revenue from its contracts. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release.

无法保证Rockwell Medical将成为血液透析浓缩物的领先全球供应商，或将从其合同中产生预期收入。尽管Rockwell Medical认为这些前瞻性陈述是合理的，但不应过分依赖任何此类前瞻性陈述，这些陈述是基于本版本发布之日我们可获得的信息。

These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different.

这些前瞻性陈述是基于目前的估计和假设，并受到各种风险和不确定性的影响（包括但不限于Rockwell Medical SEC文件中提出的那些风险和不确定性），其中许多风险和不确定性超出了我们的控制范围并可能发生变化。实际结果可能会有很大不同。

Risks and uncertainties include, but are not limited to those risks more fully discussed in the 'Risk Factors' section of our Annual Report on Form 10-K for the year ended December 31, 2022, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law..

风险和不确定性包括但不限于我们在2022年12月31日结束年份的10-K年度报告“风险因素”部分中更充分讨论的风险，因为此类描述可能会在任何我们向SEC提交的未来报告Rockwell Medical明确拒绝任何更新我们前瞻性声明的义务，除非法律可能要求。。